Enabling technologies in drug discovery: The technical and cultural integration of the new with the old

Comprehensive Medicinal Chemistry II

Volumn 2, Issue , 2006, Pages 265-287

  Williams, M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958228000     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (113)

1. Kubinyi, H. Nat. Rev. Drug Disc. 2003, 2, 665-668.
2. Lutz, M.; Kenakin, P Quantitative Molecular Pharmacology and Informatics in Drug ; Wiley: Chichester, UK, 1999.
3. Milne, G. M., Jr. Annu. Rep. Med. Chem. 2003, 38, 383-396.
4. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W et al. International Human Genome Sequencing Consortium. Nature 2001, 409, 860-921.
5. Venter, C.; Adams, M. D.; Myers, E. W; Li, P. W; Mural, R. J.; Sutton, G. G.; Smith, H. O.; Yandell, M.; Evans, C. A.; Holt, R. A. et al. Science 2002, 291, 1304-1351.
6. Collins, F S.; Green, E. D.; Guttmacher, A. E.; Guyer, M. S. Nature 2003, 422, 835-847.
7. Kramer, R.; Cohen, D. Nat. Rev. Drug Disc. 2004, 3, 965-972.
8. Stoughton, R. B.; Friend, S. H. Nat. Rev. Drug Disc. 2005, 4, 345-350.
9. Carney, S. Drug Disc. Today 2005, 10, 1025-1029.
10. Weatherall, D. Royal Society, London, 2005. http://www.royalsoc.ac.uk/(accessed Aug 2006).
11. Jones, S. Milbank Memorial Fund Report, June, 2000.
12. Figeys, D. In Industrial Proteomics; Figeys, D., Ed.; Wiley-Interscience: Hoboken, NJ, 2005, pp 1-62.
13. Huber, L. A. Nat. Rev. Mol. Cell Biol. 2003, 4, 74-80.
14. Jeffery, D. A.; Bogyo, M. Curr. Opin. Biotechnol. 2003, 14, 87-95.
15. Kopec, K.; Bozyczko-Coyne, D. B.; Williams, M. Biochem. Pharmacol. 2005, 69, 1133-1139.
16. O'Connor, K. A.; Roth, B. L. Nat. Rev. Drug Disc. 2005, 4, 1005-1014.
17. Rual, J.-F; Venkatesan, K.; Hao, T Nature 2005, 437, 1173-1179.
18. Jones, P A.; Martienssen, R. Cancer Res. 2005, 65, 11241-11246.
19. Linden, A.; Fenn, J. Research ID R-20-197; Gartner: Stamford, CT, 2003.
20. Wilmut, R., Eds., All The Words. The Complete Monty Python's Flying Circus·; Pantheon: New York, 1989; Vol. 2, pp 63-64.
21. Borman, S. Chem. Eng. News, June 19, 2006, pp 56/78.
22. Goozner, M. The $800 Million Pill: The Truth Behind the Cost of New Drugs; University of California Press: Berkeley, CA, 2004.
23. Avorn, J. Powerful Medicines: The Benefits, Risk and Costs of Prescription Drugs; Knopf: New York, 2004.
24. Horrobin, D. F Nat. Biotechnol. 2001, 19, 1099-1100.
25. Horrobin, D. F. Nat. Rev. Drug Disc. 2003, 2, 151-154.
26. Drews, J. Drug Disc. Today 2003, 8, 411-420.
27. Williams, M. Curr. Opin. Investig. Drugs 2004, 5, 1-3.
28. FitzGerald, G. A. Nat. Rev. Drug Disc. 2005, 4, 815-818.
29. Schmid, E. F; Smith, D. A. Drug Disc. Today 2005, 10, 1031-1039.
30. Williams, M. Biochem. Pharmacol. 2005, 70, 1707-1716.
31. Lowe, D. B. Contract Pharma, October 2005, 28/30. com (accessed July 2006).
32. Van der Greef, J.; McBurney, R. N. Nat. Rev. Drug Disc. 2005, 4, 961-967.
33. Sneader, W. Drug Discovery: The Evolution of Modern Medicines; Wiley: Chichester, UK, 1985.
34. Triggle, D. Curr. Protocol Pharmacol. 1998, 9.1.
35. Monaghan, R. L.; Barrett, J. F Biochem. Pharmacol. 2006, 71, 901-909.
36. In Vivo Pharmacology Training Group. Trends Pharmacol. Sci. 2002, 23, 13-18.
37. Kenakin, T. A. Pharmacology Primer. Theory, Application and Methods; Elsevier/Academic Press: San Diego, CA, 2004.
38. Gaddum, J. H. Nature 1954, 173, 14-15.
39. Stockwell, B. R. Nat. Rev. Genet. 2000, 1, 116-125.
40. Brent, R. Nat. Biotechnol. 2004, 22, 1211-1214.
41. Zambrowicz, B. P.; Sands, A. T Nat. Rev. Drug Disc. 2003, 2, 38-51.
42. Posner, B. A. Curr. Opin. Drug Disc. Dev. 2005, 8, 487-494.
43. Butcher, E. C. Nat. Rev. Drug Disc. 2005, 4, 461-467.
44. Kola, I.; Landis, J. Nat. Rev. Drug Disc. 2004, 3, 711-716.
45. Black, J. J. Med. Chem. 2005, 48, 1687-1688.
46. Wong, D. T; Perry, K. W; Bymaster, F P. Nat. Rev. Drug Disc. 2005, 4, 764-774.
47. Economist. Economist, Nov 4, 2004.
48. Topol, E. J. N. Engl. J. Med. 2005, 351, 1707-1709.
49. Pipes, S. C. Miracle Cure; Pacific Research Institute: San Francisco, CA, 2004.
50. Light, D. W; Lexchin, J. Br. Med. J. 2005, 331, 958-960.
51. G. Colvin, Fortune, Nov 1, 2004, p 82.
52. Lichtenber http://ssrn.com/abstract=315993 (accessed April 2006).
53. Stephens, B. The Wall Street Journal, Jan 7-8, 2006, p A6.
54. Ranalli, P., 1999 html (accessed April 2006).
55. Bjorklund, A.; Lindvall, O. Nat. Neurosci. 2000, 3, 537-544.
56. Normile, D.; Vogel, G.; Holden, C. Science 2005, 310, 1886-1887.
57. Kay, J., 1998. com/society/133 (accessed April 2006).
58. Zerhouni, E. Science 2003, 302, 63-72.
59. Couzin, J. Science2003, 302, 218-221.
60. FDA. Innovation/Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products; FDA: Bethesda, MD, April, 2004 http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (accessed April 2006).
61. Jensen, I.; Jorgenson, S.; Sapienza, A. Drug Dev. Res. 1998, 35, 1-6.
62. Sams-Dodd, F Drug Disc. Today 2005, 10, 1049-1056.
63. Sapienza, A. R&D Mgrnt. 2005, 35, 473-482.
64. Firestein, G. S.; Pisetsky, D. S. Arthritis Rheum. 2002, 46, 859-861.
65. Lazo, J. S.; Ducruet, A. P.; Koldamova, R. P Mol. Pharmacol. 2003, 64, 199-201.
66. Maddox, J. Nature 1992, 335, 201.
67. Preusch, P. C. Mol. Interventions 2004, 4, 72-73.
68. Jobe, P C.; Adams-Curtis, L. E.; Burks, T F; Fuller, R. W; Peck, C. C.; Ruffolo, R. R.; Snead, O. C., III; Woosley, R. L. Physiologist 1994,37, 79-84.
69. Prud'homme, A. The Cell Game\ HarperCollins: New York, 2004.
70. Williams, M. Curr. Opin. Investig. Drugs 2006, 7, 1-4.
71. Chumakov, I.; Blumenfeld, M.; Guerassimenko, O.; Cavarec, L.; Palicio, M.; Abderrahim, H.; Bougueleret, L.; Barry, C.; Tanaka, H.; La Rosa, P et al. Proc. Natl. Acad. Sei. USA 2002, 99, 13675-13680.
72. Tsai, G.; Coyle, J. T. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 165-179.
73. Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J. P. Nat. Rev. Drug Disc. 2005, 4, 107-120.
74. Lloyd, G. L.; Williams, M. J. Pharmacol. Exp. T'her. 2000, 292, 461-467.
75. Caulfield, M. P; Birdsall, N. J. M. Pharmacol Rev. 1998, 50, 279-290.
76. Roth, B. L.; Sheffler, D. J.; Kroeze, W K. Nat. Rev. Drug Disc. 2004, 3, 353-359.
77. Fritz, S. Nature 2005, 437, 942-943.
78. Carter, T A.; Wodicka, L. M.; Shah, N. P; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V; Atteridge, C. E.; Biggs, W H., III; Edeen, P. T et al. Proc. Natl. Acad. Sei. USA 2005, 102, 11011-11016.
79. Weiner, D. M.; Meltzer, H. Y; Veinbergs, I.; Donohue, E. M.; Spalding, T A.; Smith, T. T; Mohell, N.; Harvey, S. C.; Lameh, J.; Nash, N. et al. Psychopharmacology 2004, 177, 207-216.
80. Fabian, M. A.; Biggs, W H., III; Treiber, D. K.; Atteridge, C. E.; Azimiora, M. D.; Benedetti, M. G.; Carter, T A.; Ciceri, P; Edeen, P. T.; Floyd, M. et al. Nat. Biotechnol. 2005, 23, 329-336.
81. Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523-6543.
82. Irwin, S. Psychopharmacologia 1968, 13, 222-257.
83. Giardina, W. J.; Dart, M. J.; Harris, R. R.; Bitner, R. S.; Radek, R. J.; Fox, G. B.; Chemburkar, S. R.; Marsh, K. C.; Waring, J. F; Hui, J. Y et al. Epilepsia 2005, 46, 1349-1361.
84. Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y H.; Bergles, D. E.; Jin, L.; Hoberg, M. D.; Vidensky, S.; Chung, D. S. et al. Nature 2005, 433, 73-77.
85. Hara, M. R.; Thomas, B.; Cascio, M. B.; Bae, B.-L.; Hester, L. D.; Dawson, V L.; Dawson, T. M.; Sawa, A.; Snyder, S. H. Proc. Natl. Acad. Sei. USA 2006, 103, 3887-3889.
86. McGeer, P. L.; McGeer, E.; Rogers, J.; Sibley, J. Lancet 1990, 335, 1037.
87. Ashburn, T T; Thor, K. N. Nat. Rev. Drug Disc. 2004, 3, 673-683.
88. Keith, C. T; Borisy, A. A.; Stockwell, B. R. Nat. Rev. Drug Disc. 2005, 4, 71-78.
89. Spedding, M.; Jay, T; Costa e Silva, J.; Perret, L. Nat. Rev. Drug Disc. 2005, 4, 467-478.
90. Powell, S. B.; Risbrough, V. B.; Geyer, M. A. Clin. Neurosci. Res. 2003, 3, 289-296.
91. Porsolt, R. D.; Anion, G.; Blavet, N.; Jalfre, M. Eur. J. Pharmacol. 1977, 47, 379-391.
92. Cryan, J. F; Holmes, A. Nat. Rev. Drug Disc. 2005, 4, 775-790.
93. Porsolt, R.; Williams, M. 2005.http://www.xpharm.com/citationFArticleID=119961 (accessed March 2006).
94. Leaf, C. Fortune, Sept 19, 2005, pp 250-268.
95. Economist, Dec 20, 2005, p 109.
96. Heller, M. A.; Eisenberg, R. S. Science 1998, 280, 698-701.
97. Surowiecki, J. New Yorker, Dec 26, 2005, p 50.
98. Kesselheim, A. S.; Avorn, J. JAMA. 2005, 293, 850-854.
99. Paradise, J.; Andrews, L.; Holbrook, T. Science 2005, 307, 1566-1567.
100. Bussey, P.; Pisani, J.; Bonduelle, Y. In Industrialization of Drug Discery: from Target Selection through Lead ; Handen, J. S., Ed.; CRC Press/Taylor and Francis: Boca Raton, FL, 2005, pp 191-218.
101. Kenakin, T. Pharmacol. Rev. 1996, 48, 413-463.
102. Angers, S.; Salahpour, A.; Bouvier, M. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 409-435.
103. Maudsley, S.; Martin, B.; Luttrell, L. M. J. Pharmacol. Exp. Ther. 2005, 314, 485-494.
104. Settleman, J. Drug Disc. Today: Disease Mechanisms 2005, 2, 139-144.
105. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Drug Disc. Today 2005, 10, 839-846.
106. Pocklington, A. J.; Cumiskey, M.; Armstrong, J. D.; Grant, S. G. N. Mol. Syst. Biol. 2006, 2, 2006.0023.
107. Kenakin, T Nat. Rev. Drug Disc. 2005, 4, 919-927.
108. Handen, J. S. In Industrialization of Drug Discovery: from Target Selection through Lead Optimization; Handen, J. S., Ed.; CRC Press/Taylor and Francis: Boca Raton, FL, 2005, pp 1-12.
109. Duyk, G. Science 2003, 302, 603-605.
110. Jennings, M. M.; Grossman, L. The Wall Street Journal, June 26, 1995, p A12.
111. Mullin, R. Chem. Eng. News, June 19, 2006, pp 30/55.
112. FDA: Criticalhttp://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf (accessed June 2006).
113. Parker-Pope, T. The Wall Street Journal, February 28, 2006, pp A1/A13.